Liquiritigenin inhibits tumor growth and vascularization in a mouse model of HeLa cells

Molecules

Volumn 17, Issue 6, 2012, Pages 7206-7216

  Liu, Yuxin ^a   Xie, Sirou ^a   Wang, Yu ^a   Luo, Kang ^a   Wang, Yang ^a   Cai, Yunqing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Cervical cancer; Liquirtigenin; Vascular endothelial growth factor (VEGF)

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FLAVANONE DERIVATIVE; LIQUIRITIGENIN; VASCULOTROPIN A;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; HELA CELL; HUMAN; MICROVASCULATURE; MOUSE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; FLAVANONES; HELA CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROVESSELS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862995991     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules17067206     Document Type: Article

References (32)

1. Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002, 29, 15-18.
2. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 1990, 82, 4-6. (Pubitemid 20020880)
3. Holmgren, L.; O'Reilly, M. S.; Folkman, J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1995, 1, 149-153.
4. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
5. Bhat, T. A.; Singh, R. P. Tumor angiogenesis-A potential target in cancer chemoprevention. Food Chem. Toxicol. 2008, 46, 1334-1345. (Pubitemid 351258200)
6. Korpanty, G.; Smyth, E. Anti-VEGF Strategies-From Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer. Curr. Pharm. Des. 2012, 18, 2680-2701.
7. Bergers, G.; Song, S.; Meyer-Morse, N.; Bergsland, E.; Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 2003, 111, 1287-1295. (Pubitemid 36554699)
8. Kamba, T.; McDonald, D. M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 2007, 96, 1788-1795. (Pubitemid 46912024)
9. Summers, J.; Cohen, M. H.; Keegan, P.; Pazdur, R. FDA drug approval summary: Bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist 2010, 15, 104-111.
10. Ramos, S. Cancer chemoprevention and chemotherapy: Dietary polyphenols and signalling pathways. Mol. Nutr. Food Res. 2008, 52, 507-526.
11. Prasad, S.; Phromnoi, K.; Yadav, V. R.; Chaturvedi, M. M.; Aggarwal, B. B. Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer. Planta Med. 2010, 76, 1044-1063.
12. Kim, Y. W.; Kang, H. E.; Lee, M. G.; Hwang, S. J.; Kim, S. C.; Lee, C. H.; Kim, S. G. Liquiritigenin, a flavonoid aglycone from licorice, has a choleretic effect and the ability to induce hepatic transporters and phase-II enzymes. Am. J. Physiol. Gastrointest. Liver. Physiol. 2009, 296, G372-G381.
13. Kim, Y. W.; Kim, Y. M.; Yang, Y. M.; Kay, H. Y.; Kim, W. D.; Lee, J. W.; Hwang, S. J.; Kim, S. G. Inhibition of LXRalpha-dependent steatosis and oxidative injury by liquiritigenin, a licorice flavonoid, as mediated with Nrf2 activation. Antioxid. Redox Signal. 2011, 14, 733-745.
14. Zhang, S. P.; Zhou, Y. J.; Liu, Y.; Cai, Y. Q. Effect of liquiritigenin, a flavanone existed from Radix glycyrrhizae on pro-apoptotic in SMMC-7721 cells. Food Chem. Toxicol. 2009, 47, 693-701.
15. Liu, C.; Wang, Y.; Xie, S.; Zhou, Y.; Ren, X.; Li, X.; Cai, Y. Liquiritigenin induces mitochondria-mediated apoptosis via cytochrome c release and caspases activation in HeLa Cells. Phytother. Res. 2011, 25, 277-283.
16. Zhou, M.; Higo, H.; Cai, Y. Inhibition of hepatoma 22 tumor by Liquiritigenin. Phytother. Res. 2010, 24, 827-833.
17. Xie, S. R.; Wang, Y.; Liu, C. W.; Luo, K.; Cai, Y. Q. Liquiritigenin Inhibits Serum-induced HIF-1alpha and VEGF Expression via the AKT/mTOR-p70S6K Signalling Pathway in HeLa Cells. Phytother. Res. 2011, doi:10.1002/ptr.3696.
18. Wang, Y.; Xie, S.; Liu, C.; Wu, Y.; Liu, Y.; Cai, Y. Inhibitory Effect of Liquiritigenin on Migration Via Downregulation ProMMP-2 and PI3K/Akt Signaling Pathway in Human Lung Adenocarcinoma A549 cells. Nutr. Cancer 2012, 64, 627-634.
19. Shultz, M. D.; Wilson, J. D.; Fuller, C. E.; Zhang, J.; Dorn, H. C.; Fatouros, P. P. Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging in a murine orthotopic xenograft model. Radiology 2011, 261, 136-143.
20. Tarallo, V.; Vesci, L.; Capasso, O.; Esposito, M. T.; Riccioni, T.; Pastore, L.; Orlandi, A.; Pisano, C.; De Falco, S. A placental growth factor variant unable to recognize vascular endothelial growth factor (VEGF) receptor-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization. Cancer Res. 2010, 70, 1804-1813.
21. Kang, S. Y.; Watnick, R. S. Regulation of tumor dormancy as a function of tumor-mediated paracrine regulation of stromal Tsp-1 and VEGF expression. APMIS 2008, 116, 638-647.
22. Guan, P.; Howell-Jones, R.; Li, N.; Bruni, L.; De Sanjose, S.; Franceschi, S.; Clifford, G. M. Human papillomavirus (HPV) types in 115, 789 HPV-positive women: A meta-analysis from cervical infection to cancer. Int. J. Cancer 2012, doi:10.1002/ijc.27485.
23. Joo, Y. H.; Jung, C. K.; Sun, D. I.; Park, J. O.; Cho, K. J.; Kim, M. S. High-risk human papillomavirus and cervical lymph node metastasis in patients with oropharyngeal cancer. Head Neck 2012, 34, 10-14.
24. Hisamatsu, T.; Mabuchi, S.; Yoshino, K.; Fujita, M.; Enomoto, T.; Hamasaki, T.; Kimura, T. Prediction of Progression-Free Survival and Response to Paclitaxel Plus Carboplatin in Patients With Recurrent or Advanced Cervical Cancer. Int. J. Gynecol. Cancer 2012, 22, 623-629.
25. Mathur, R. S.; Mathur, S. P. Vascular endothelial growth factor (VEGF) up-regulates epidermal growth factor receptor (EGF-R) in cervical cancer in vitro: This action is mediated through HPV-E6 in HPV-positive cancers. Gynecol. Oncol. 2005, 97, 206-213. (Pubitemid 40403696)
26. Bachtiary, B.; Selzer, E.; Knocke, T. H.; Potter, R.; Obermair, A. Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: Impact on progression-free survival. Cancer Lett. 2002, 179, 197-203. (Pubitemid 34215111)
27. Clere, N.; Faure, S.; Martinez, M. C.; Andriantsitohaina, R. Anticancer properties of flavonoids: Roles in various stages of carcinogenesis. Cardiovasc. Hematol. Agents Med. Chem. 2011, 9, 62-77.
28. Gao, L.; Chen, L.; Fei, X. H.; Qiu, H. Y.; Zhou, H.; Wang, J. M. STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model. Chin. Med. J. (Engl) 2006, 119, 911-918. (Pubitemid 43880969)
29. Villaume, K.; Blanc, M.; Gouysse, G.; Walter, T.; Couderc, C.; Nejjari, M.; Vercherat, C.; Cordier-Bussat, M.; Roche, C.; Scoazec, J. Y. VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway. Neuroendocrinology 2010, 91, 268-278.
30. Ferrara, N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev. 2010, 21, 21-26.
31. Donmez, G.; Sullu, Y.; Baris, S.; Yildiz, L.; Aydin, O.; Karagoz, F.; Kandemir, B. Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas. Pathol. Res. Pract. 2009, 205, 854-847.
32. Karavasilis, V.; Malamou-Mitsi, V.; Briasoulis, E.; Tsanou, E.; Kitsou, E.; Kalofonos, H.; Fountzilas, G.; Fotsis, T.; Pavlidis, N. Angiogenesis in cancer of unknown primary: Clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer 2005, 5, 25.